Catalyst Dossier · compiled by Celia 🧫

BeOne Medicines Ltd. (ONC)

Pharmaceutical Preparations · market cap $390.4B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

BeOne Medicines (formerly BeiGene) is a multinational oncology company with ~11,000 employees, headquartered in Cambridge, MA, with a major presence in China and operations across 45+ countries. The company generated $5.34B in revenue in 2025, its first profitable year ($287M net income), with a pipeline centered on hematologic malignancies and solid tumors. Key upcoming catalysts include Phase 2 readouts for Tacrolimus in Primary Membranous Nephropathy and BGB-16673 in B-cell Malignancies in late 2026.

The catalyst path

2026-08-05Earningsimp 5/10
2026-09-22 (est.)Phase 2 · Tacrolimusimp 7/10
2026-11-15 (est.)Phase 2 · BGB-16673imp 7/10

Pipeline

Asset	Phase	Indication
Zanubrutinib	Phase 2	Chronic Lymphocytic Leukemia
Venetoclax	Phase 3	CLL
BGB-16673	Phase 3	B-cell Malignancy
Tacrolimus	Phase 3	Primary Membranous Nephropathy
Subcutaneous Tislelizumab	Phase 3	Metastatic Gastric Adenocarcinoma
Pirtobrutinib	Phase 3	Chronic Lymphocytic Leukemia
Dexamethasone	Phase 2	Relapsed/Refractory Multiple Myeloma
Bendamustine	Phase 3	CLL
Sonrotoclax	Phase 3	Mantle Cell Lymphoma
Capecitabine	Phase 2	Advanced Unresectable Gastric Adenocarcinoma
Tislelizumab	Phase 3	Advanced Malignancies
BGB-43395	Phase 3	HR+/HER2- Breast Cancer

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.